Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
IFOM ETS - The AIRC Institute of Molecular Oncology
Accent Therapeutics
Vividion Therapeutics, Inc.
Nimbus Therapeutics
ImmunityBio, Inc.
Merck Sharp & Dohme LLC
GERCOR - Multidisciplinary Oncology Cooperative Group
University of Pittsburgh
Marengo Therapeutics, Inc.
GERCOR - Multidisciplinary Oncology Cooperative Group
Gruppo Oncologico del Nord-Ovest
M.D. Anderson Cancer Center
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Blokhin's Russian Cancer Research Center
UNICANCER
Assistance Publique - Hôpitaux de Paris
Fate Therapeutics
Royal Marsden NHS Foundation Trust
Incyte Corporation
Incyte Corporation
University of Washington